Pfizer's strategy and innovation officer Andrew Baum to leave drugmaker, analyst note says

April 20 (Reuters) - Pfizer's Chief Strategy and Innovation Officer, Andrew Baum, is transitioning to a new role and will ...

Pfizer, Astellas win FDA priority review for Padcev in bladder cancer with Merck’s Keytruda

Pfizer (PFE) and Astellas (ALPMF) (ALPMY) announced Monday that the FDA has granted priority review for their marketing application, which seeks U.S. approval for their antibody drug conjugate, Padcev ...
AOL

Exclusive-Pfizer, BioNTech halt US COVID vaccine study after recruitment struggles

LONDON, April 1 (Reuters) - Vaccine makers Pfizer and BioNTech halted a large U.S. trial of their updated COVID-19 vaccine in healthy adults aged 50 to 64, saying enrollment in the trials had been too ...

Pfizer, BioNTech end U.S. COVID vaccine trial over low participation: Reuters

Pfizer (PFE) stock and BioNTech (BNTX) stock are in focus as a large U.S. trial for the companies' updated COVID-19 vaccine ...
FiercePharma

Pfizer confirms patient death in Hympavzi hemophilia extension study

A patient in an open label extension study of Pfizer’s hemophilia treatment Hympavzi has died, the company and several hemophilia advocacy groups confirmed this week. Pfizer is now working with its ...
The Motley Fool

Where Will Pfizer Be in 5 Years?

Pfizer's stock soared during the coronavirus pandemic because of its COVID-19 vaccine. The world has learned to live with the coronavirus, and Pfizer's stock has plunged as a result. Faced with patent ...
RAPS

Recon: Pfizer to boost US vaccine deliveries as EU secures more doses; Tango to go public in $353M SPAC deal

Recon: Pfizer to boost US vaccine deliveries as EU secures more doses; Tango to go public in $353M SPAC deal Welcome to Regulatory Reconnaissance, your daily regulatory news and intelligence briefing.
Scientific American

Lyme disease is spreading—a new vaccine could curb infections

A new Lyme disease vaccine made by Pfizer and Valneva could lower infection rates of the tick-borne illness, but federal approval and patient uptake could be a challenge ...
The Motley Fool

Should You Avoid Pfizer? Here's the Key Risk to Watch

Pfizer’s revenue reached $100 billion a few years ago, driven by its dominance in coronavirus treatments and prevention. In recent times, it’s faced a drop in that demand and losses of exclusivity ...
FiercePharma

Pfizer eyes earlier Talzenna use after phase 3 prostate cancer win

Pfizer is eyeing an earlier use of its PARP inhibitor Talzenna after a positive phase 3 trial in metastatic hormone-sensitive prostate cancer (mHSPC). The phase 3 Talapro-3 trial met its primary ...
Seeking Alpha

Pfizer reports positive data from a Phase 2 study for the atopic dermatitis antibody

Pfizer (PFE) said its Phase 2 study of tilrekimig (PF-07275315), a trispecific antibody for atopic dermatitis, showed positive results. The study met its primary endpoint, with tilrekimig showing a ...